Treatments for neurogenetic disorders, impulse control disorder, and wound healing

Abstract

The subject invention provides methods and compositions for the treatment of neurogenetic disorders, particularly DSM-IV impulse control disorders such as intermittent explosive disorder, kleptomania, pyromania, pathologic gambling, trichotillomania, and other impulse control disorders such as compulsive buying and problematic Internet use. In a preferred embodiment, the subject invention provides methods for treating or controlling symptoms associated with ADHD or PWS comprising the administration of therapeutically effective amounts of compositions containing compounds of the formulas I-V. In another embodiment, the subject invention provides for methods of promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising the compounds of formulas I-V. Compositions may administered to a wound site via a salve, ointment, or as a component of a bandage or bioadhesive applied to the site of injury. The invention also provides therapeutically effective compositions comprising one or more of the compounds of formulas I-V.

What is claimed is:  
     
         1 . A method for treating or controlling neurogenetic disorders in an individual comprising the administration of a therapeutically effective amount of a composition comprising an anti-convulsant agent and a pharmaceutically acceptable carrier.  
     
     
         2 . The method according to  claim 1 , wherein said neurogenetic disorder is compulsive buying, problematic Internet use, or an impulse control disorder selected from the group consisting of intermittent explosive disorder, kleptomania, pyromania, pathologic gambling, and trichotillomania.  
     
     
         3 . The method according to  claim 1 , wherein said neurogenetic disorder is Prader-Willi Syndrome.  
     
     
         4 . The method according to  claim 1 , wherein said neurogenetic disorder is attention deficit hyperactivity disorder.  
     
     
         5 . The method according to  claim 1 , wherein said anti-convulsant agent is selected from the group consisting of:  
       
         
           
           
               
               
           
         
       
       wherein 
 X 1  is CH 2  or oxygen;  
 R 1  is hydrogen or alkyl; and  
 R 2 , R 3 , R 4 , and R 5  are independently hydrogen or lower alkyl and, R 2  and R 3  and/or R 4  and R 5  together may be a methylenedioxy group of the following formula:  
                     
 wherein R 6  and R 7  are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring,  
                     
 wherein R 6  and R 7  may be the same or different and are hydrogen or C 1  to C 4  alkyl;  
 wherein R 8  and R 9  may be the same or different and are hydrogen or C 1  to C 4  alkyl;  
 wherein R 10  and R 11  may be the same or different and are azido, halogen, hydroxyl, sulfamoyl (H 2 NSO 2 O), C 1 to C   4  alkoxy, C 1  to C 4  alkyl thiocarbonate (RSC(O)O), C 1  to C 4  alkyl carbonate (ROC(O)O), or C 1  to C 4  alkyl carboxylate (RC(O)O), wherein R is C 1  to C 4  alkyl,  
                     
 wherein R 12  and R 13  may be the same or different and are hydrogen, alkyl (C 1 to C   6 ), cycloalkyl (C 3 -C 7 ), allyl, or benzyl;  
 R 14  and R 15  are the same or different and selected from hydrogen or lower alkyl; and  
 X 2  may be chosen from carbon (C) or sulfur (S), with the stipulation that when X 2  is carbon, R 16  and R 17  are the same or different and are selected from hydrogen or lower alkyl, whereas when X 2  is sulfur one of R 16  and R 17  is oxygen and the other is a lone pair of electrons or both R 16  and R 17  are oxygen,  
                     
 wherein, AR is represented by the following formulas;  
                     
 Y is selected from the group consisting of halogens, trifluoromethyl and alkyl groups containing 1 to 3 carbon atoms when Y alone is attached to the benzene ring; or  
 when X 3 , which may be S or O, is present, Y is selected from the group consisting of trifluoromethyl and alkyl groups containing 1 to 3 carbon atoms; and  
 R 18 , R 19 , R 20 , and R 21 , may be identical or different and are selected from the group consisting of hydrogen, linear or branched alkyl groups containing 1 to 16 carbon atoms, cyclic alkyl groups containing 3 to 16 carbon atoms and aryl groups containing 6 to 8 carbon atoms, and NR 18 R 19  and NR 20 R 21 , which may be identical or different, each may form a 3 to 7-membered aliphatic cyclic compound together with another nitrogen atom or oxygen atom.  
 
     
     
         6 . A method for promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising an anti-convulsant agent and a carrier.  
     
     
         7 . The method according to  claim 6 , wherein said anti-convulsant agent is selected from the group consisting of:  
       
         
           
           
               
               
           
         
       
       wherein 
 X 1  is CH 2  or oxygen;  
 R 1  is hydrogen or alkyl; and  
 R 2 , R 3 , R 4,  and R 5  are independently hydrogen or lower alkyl and, R 2  and R 3  and/or R 4  and R 5  together may be a methylenedioxy group of the following formula:  
                     
 wherein R 6  and R 7  are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring,  
                     
 wherein R 6  and R 7  may be the same or different and are hydrogen or C 1  to C 4  alkyl;  
 wherein R 8  and R 9  may be the same or different and are hydrogen or C 1  to C 4  alkyl;  
 wherein R 10  and R 11  may be the same or different and are azido, halogen, hydroxyl, sulfamoyl (H 2 NSO 2 O), C 1  to C 4  alkoxy, C 1 to C 4  alkyl thiocarbonate (RSC(O)O), C 1  to C 4  alkyl carbonate (ROC(O)O), or C 1  to C 4  alkyl carboxylate (RC(O)O), wherein R is C 1  to C 4  alkyl,  
                     
 wherein R 12  and R 13  may be the same or different and are hydrogen, alkyl (C 1  to C 6 ), cycloalkyl (C 3 -C 7 ), allyl, or benzyl;  
 R 14  and R 15  are the same or different and selected from hydrogen or lower alkyl; and  
 X 2  may be chosen from carbon (C) or sulfur (S), with the stipulation that when X 2  is carbon, R 16  and R 17  are the same or different and are selected from hydrogen or lower alkyl, whereas when X 2  is sulfur one of R 16  and R 17  is oxygen and the other is a lone pair of electrons or both R 16  and R 17  are oxygen,  
                     
                     
 wherein, AR is represented by the following formulas;  
                     
 Y is selected from the group consisting of halogens, trifluoromethyl and alkyl groups containing 1 to 3 carbon atoms when Y alone is attached to the benzene ring; or  
 when X 3 , which may be S or O, is present, Y is selected from the group consisting of trifluoromethyl and alkyl groups containing 1 to 3 carbon atoms; and  
 R 18 , R 19 , R 20 , and R 21 , may be identical or different and are selected from the group consisting of hydrogen, linear or branched alkyl groups containing 1 to 16 carbon atoms, cyclic alkyl groups containing 3 to 16 carbon atoms and aryl groups containing 6 to 8 carbon atoms, and NR 18 R 19  and NR 20 R 21 , which may be identical or different, each may form a 3 to 7-membered aliphatic cyclic compound together with another nitrogen atom or oxygen atom.  
 
     
     
         8 . The method according to  claim 6 , wherein said composition comprises a salve, ointment, aerosol, cosmetic, or bioadhesive.  
     
     
         9 . The method according to  claim 6 , wherein said composition is administered as a component of a bandage, transdermal patch, wound dressing, cosmetic, or bioadhesive.  
     
     
         10 . The method according to  claim 8 , wherein said composition is a component of a bandage, wound covering, or wound dressing.  
     
     
         11 . The method according to  claim 1 , wherein the therapeutically effective amount is about 0.1 to 400 mg.  
     
     
         12 . The method according to  claim 1 , wherein the therapeutically effective amount is about 10 to 200 mg.  
     
     
         13 . The method according to  claim 1 , wherein the therapeutically effective amount is about 25 mg.  
     
     
         14 . The method according to  claim 5 , wherein the therapeutically effective amount is about 0.1 to 400 mg.  
     
     
         15 . The method according to  claim 5 , wherein the therapeutically effective amount is about 10 to 200 mg.  
     
     
         16 . The method according to  claim 5 , wherein the therapeutically effective amount is about 25 mg.  
     
     
         17 . The method according to  claim 1 , wherein said neurogenic disorder is pathological skin picking and related disorders.  
     
     
         18 . The method according to  claim 1 , wherein said neurological disorders are self-injury, gouging, nail biting, explosive outbursts, oppositional behavior, or obsessive ruminations.